Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
CD20+
100%
Immunochemotherapy
100%
Limited-stage
100%
Completely Resected
100%
3-cycle
60%
R-CHOP Chemotherapy
60%
Residual Lesions
40%
Confidence Interval
40%
Disease-free Survival
40%
Lymphoma Patients
40%
Phase II Study
20%
Low Risk
20%
Low-risk Patients
20%
Neutropenia
20%
Resection
20%
Spleen
20%
Intestine
20%
Tonsil
20%
Gross Total Resection
20%
Hematotoxicity
20%
Cervical Lymph Node
20%
Overall Survival Rate
20%
International Prognostic Index
20%
Stomach
20%
Febrile Neutropenia
20%
Ineligibility
20%
R-CHOP Immunochemotherapy
20%
Nonhematologic
20%
Chemotherapy Cycles
20%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
CD20
100%
Chemotherapy
80%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
80%
Disease Free Survival
40%
Surgery
40%
Arm
20%
Neutropenia
20%
Tonsil
20%
Overall Survival
20%
Survival Rate
20%
International Prognostic Index
20%
Febrile Neutropenia
20%
Cervical Lymph Node
20%
Intestine
20%